•HRES 1150 IH 
Whereas the average 5-year survival rate for an individual in 
the United States following the diagnosis of a primary 
malignant brain tumor is only 35.6 percent; 
Whereas it is estimated that 18,200 individuals in the United 
States will die as a result of a malignant brain tumor in 
2022; 
Whereas brain tumors may be malignant or benign but can 
be life-threatening in either case; 
Whereas, as of the date of introduction of this resolution, ap-
proximately 700,000 individuals in the United States are 
living with a brain tumor; 
Whereas treatment of brain tumors is complicated by the fact 
that more than 100 types of brain tumors exist; 
Whereas the treatment and removal of brain tumors present 
significant challenges due to the uniquely complex and 
fragile nature of the brain; 
Whereas brain tumors affect the primary organ in the human 
body that controls not only cognitive ability, but the ac-
tions of every other organ and limb in the body, leading 
to brain tumors being described as a disease that affects 
the whole individual; 
Whereas brain tumor research is supported by a number of 
private, nonprofit research foundations and by Federal 
medical research institutions; 
Whereas basic research may fuel advancements and develop-
ment of new treatments for brain tumors; 
Whereas obstacles to the development of new treatments for 
brain tumors remain, and there are limited strategies for 
the screening or early detection of brain tumors; 
VerDate Sep 11 2014 
21:19 May 31, 2022
Jkt 029200
PO 00000
Frm 00002
Fmt 6652
Sfmt 6300
E:\BILLS\HR1150.IH
HR1150
pamtmann on DSKBC07HB2PROD with BILLS
•HRES 1150 IH 
Whereas, despite the high number of individuals diagnosed 
with a brain tumor every year and the devastating prog-
noses for those individuals, only 5 drugs and 1 medical 
device are approved by the Food and Drug Administra-
tion to treat primary brain tumors; 
Whereas the mortality rates associated with brain tumors 
have changed little during the 30-year period preceding 
the date of introduction of this resolution; 
Whereas there is a need for greater public awareness of brain 
tumors, including the difficulties associated with research 
on brain tumors and the opportunities for advances in 
brain tumor research and treatment; and 
Whereas May 2022, during which brain tumor advocates na-
tionwide unite in awareness, outreach, and advocacy ac-
tivities, is an appropriate month to recognize as ‘‘Na-
tional Brain Tumor Awareness Month’’: Now, therefore, 
be it 
Resolved, That the House of Representatives— 
(1) supports the designation of ‘‘National Brain 
Tumor Awareness Month’’; 
(2) encourages increased public awareness of 
brain tumors to honor the individuals who have lost 
their lives to a brain tumor or currently live with a 
brain tumor diagnosis; 
(3) supports efforts to develop better treat-
ments for brain tumors that will improve the quality 
of life and the long-term prognoses of individuals di-
agnosed with a brain tumor; 
VerDate Sep 11 2014 
21:19 May 31, 2022
Jkt 029200
PO 00000
Frm 00003
Fmt 6652
Sfmt 6201
E:\BILLS\HR1150.IH
HR1150
pamtmann on DSKBC07HB2PROD with BILLS
•HRES 1150 IH 
(4) expresses its support for individuals who are 
battling brain tumors, as well as the families, 
friends, and caregivers of those individuals; and 
(5) urges a collaborative approach to brain 
tumor research, which is a promising means of ad-
vancing understanding of, and treatment for, brain 
tumors. 
Æ 
VerDate Sep 11 2014 
21:19 May 31, 2022
Jkt 029200
PO 00000
Frm 00004
Fmt 6652
Sfmt 6301
E:\BILLS\HR1150.IH
HR1150
pamtmann on DSKBC07HB2PROD with BILLS